Page last updated: 2024-12-07
s-benzyl-l-cysteine-4'-nitroanilide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
S-benzyl-L-cysteine-4'-nitroanilide: substrate for cystine aminopeptidase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 81941 |
| SCHEMBL ID | 1158102 |
| MeSH ID | M0045669 |
Synonyms (28)
| Synonym |
|---|
| l-2-amino-3-(benzylthio)-4'-nitropropionanilide |
| s-benzyl-l-cysteine-4'-nitroanilide |
| propanamide, 2-amino-n-(4-nitrophenyl)-3-((phenylmethyl)thio)-, (2r)- |
| (r)-2-amino-3-benzylthio-n-(4-nitrophenyl)propionamide |
| einecs 231-090-1 |
| h-cys(bzl)-pna |
| s-benzyl-n-(4-nitrophenyl)-l-cysteinamide |
| 7436-62-6 |
| s-benzyl-l-cysteine-p-nitroanilide |
| (2r)-2-amino-3-benzylsulfanyl-n-(4-nitrophenyl)propanamide |
| A838104 |
| s-benzyl-l-cysteine p-nitroanilide |
| AKOS015888853 |
| s-benzyl-l-cysteine 4-nitroanilide |
| propanamide, 2-amino-n-(4-nitrophenyl)-3-[(phenylmethyl)thio]-, (2r)- |
| SCHEMBL1158102 |
| s-benzyl-l-cysteine-4-nitroaniline |
| HOZQMLJHNCMSRC-HNNXBMFYSA-N |
| 2-amino-3-(benzylsulfanyl)-n-(4-nitrophenyl)propanamide # |
| propanamide, 2-amino-n-(4-nitrophenyl)-3-[(phenylmethyl)thio]-, (r)- |
| FD21322 |
| mfcd00007302 |
| CS-0204412 |
| propanamide,2-amino-n-(4-nitrophenyl)-3-[(phenylmethyl)thio]-,(2r)- |
| (r)-2-amino-3-(benzylthio)-n-(4-nitrophenyl)propanamide |
| AS-49037 |
| DTXSID30883500 |
| l-cys(bzl)-pna |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Secondary endpoints included immunologic function, improvement in HRQoL on day 21 and 84, objective response rate, disease control rate, BMI and adverse events." | ( Safety and efficacy of spleen aminopeptide oral lyophilized powder for improving quality of life and immune response in patients with advanced breast cancer: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cao, B; Ma, X; Ma, Y; Ma, Z; Shang, K; Wang, J; Wu, S, 2021) | 0.62 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 8 (80.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.79
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.79) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||